NasdaqCM - Nasdaq Real Time Price ? USD IceCure Medical Ltd (ICCM) Follow Compare 0.6000 -0.0074 (-1.22%) At close: November 18 at 4:00 PM EST 0.6000 0.00 (0.00%) After hours: November 18 at 4:48 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations IceCure’s cryoablation?system for breast cancer treatment gains FDA panel support Based on the latest recommendation, the company anticipates receiving marketing authorisation for the system in the first quarter of 2025. Medical Device Network ? 7 days ago ICCM -1.22% FDA Advisory Panel Votes in Favor of IceCure's ProSense? Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced the U.S. Food and Drug Administration's ("FDA") Medical Device Advisory Committee Panel's (the "Advisory Panel") favorable recommendation with 9 panelists voting in favor and 5 voting against the benefit-risk profile of IceCure's ProSense?. The majority of panelists vote PR Newswire ? 10 days ago ICCM -1.22% Upcoming FDA Advisory Panel for IceCure's ProSense? Marketing Authorization Receives Large Number of Public Comments from Stakeholders IceCure Medical Ltd. (NASDAQ: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that a large number of public comments have been posted from key stakeholders ahead of the U.S. Food and Drug Administration (the 'FDA') Medical Device Advisory Committee Panel (the 'Advisory Panel') for marketing authorization of ProSense? cryoablation in early-st PR Newswire ? 20 days ago ICCM -1.22% IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance for its invention titled "Cryogenic System Connector" from the U.S. Patent and Trademark Office. This is the first global patent issued for the cryogenic system connector, a key component of IceCure's next-generation liquid nit PR Newswire ? 28 days ago ICCM -1.22% Alignment HealthCare Partners With Intermountain Health in Nevada ALHC partners with Intermountain Health to enhance access to high-quality care for Medicare members in Clark and Washoe counties, starting Jan 2025. Zacks ? last month CODX ICCM -1.22% HQY IceCure's ProSense? Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that IceCure's ICE3 trial and five additional studies featuring new data on ProSense's? use in breast cancer and fibroadenoma were presented at the 2024 European Society of Breast Imaging (EUSOBI) Scientific Meeting and Annual Conference which took place in Lisbon, PR Newswire ? last month ICCM -1.22% Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic have been highlighted in this Screen of The Week article. Zacks ? last month ICCM -1.22% DRIO WATT IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense? Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an article titled, "Cryoablation Without Excision for Early–Stage Breast Cancer: ICE3 Trial 5–Year Follow–Up on Ipsilateral Breast Tumor Recurrence" in the Annals of Surgical Oncology, the official journal of the Society of Surgical Oncology. The PR Newswire ? last month ICCM -1.22% Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense? is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study led by Dr. Franco Orsi, Director of Interventional Radiology at the European Institute of Oncology (IEO) in Milan, Italy and an expert ProSense? user. The study titled "Liquid Nitrogen-Based Cryoablation: Complication Rates f PR Newswire ? 2 months ago ICCM -1.22% IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense? in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the U.S. Food and Drug Administration's ("FDA") Medical Device Advisory Committee Panel (the "Advisory Panel") is scheduled to take place on Thursday, November 7, 2024. The purpose of the Advisory Panel is for the FDA to obtain independent expert advice on scientif PR Newswire ? 2 months ago ICCM -1.22% IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the Company's Chief Executive Officer, Eyal Shamir, will conduct one-on-one meetings with institutional investors at both the H.C. Wainwright and Lake Street Capital Markets conferences, while the Company's Chief Financial Officer and Chief Operating Officer, PR Newswire ? 2 months ago ICCM -1.22% USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for a continuation application based on the Company's issued patent titled "Cryogen Pump". The original patent, which was also issued by the European Patent Office and the Jap PR Newswire ? 2 months ago ICCM -1.22% IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates IceCure Medical (ICCM) delivered earnings and revenue surprises of 14.29% and 12.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago ICCM -1.22% IceCure Medical Reports 20% Growth in ProSense? System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2024. PR Newswire ? 2 months ago ICCM -1.22% IceCure's ProSense? Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled "Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients" in the British Journal of Radiology, a publication of the British Institute of Radiology. The single-site study PR Newswire ? 3 months ago ICCM -1.22% IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2024 before the Nasdaq Stock Market opens on Tuesday, August 20, 2024. The Company will also discuss such results and other corporate developments on a conference ca PR Newswire ? 3 months ago ICCM -1.22% IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials" IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials: A Multi-institutional Study" in a leading radiology journal, the American Journal of Roentgenology (AJR). PR Newswire ? 3 months ago ICCM -1.22% IceCure presents hat-trick of positive trial data for cryoablation device The data announcement comes on the same day the Israeli company received a Nasdaq non-compliance warning. Medical Device Network ? 3 months ago ICCM -1.22% 99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense? Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that key findings from three clinical studies of ProSense? in the treatment of breast cancer were presented at the 32nd Annual Meeting of the Japanese Breast Cancer Society on July 12, 2024 in Miyagi, Japan. PR Newswire ? 3 months ago ICCM -1.22% IceCure Medical receives Nasdaq compliance notice The Nasdaq notice indicates that the company has 180 days to regain compliance with the minimum bid price requirement. Medical Device Network ? 3 months ago ICCM -1.22% Performance Overview Trailing total returns as of 11/18/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ICCM S&P 500 YTD -43.93% +23.56% 1-Year -18.92% +30.56% 3-Year -89.93% +25.70%
